

## Summary statistics - qualitative results

(Groups: manufacturer of kit)

## EQA round: HS2/21 - Haemocoagulation Special

Deadline: 19.11.2021

|      |   |   |
|------|---|---|
| Key: | >>> ... marks correct (expected) result               | N ... number of the results             |
|      | > ... marks conditionally correct (acceptable) result | Nrel ... relative number of the results |
|      | ± ... marks the result not evaluated                  |   |

## Test

| Sample | Group | N | Result | N <sub>rel</sub> |
|--------|-------|---|--------|------------------|
|--------|-------|---|--------|------------------|

## Set 3

## (488) APC - resistance

|                          |                                     |     |               |       |
|--------------------------|-------------------------------------|-----|---------------|-------|
| A3                       | (38) IL                             | >>> | 10 Negative   | 16 %  |
|                          | (51) Technoclone                    | >>> | 2 Negative    | 3,3 % |
|                          | (94) Stago                          | >>> | 4 Negative    | 6,6 % |
|                          | (102) Chromogenix                   | >>> | 2 Negative    | 3,3 % |
|                          | (149) Siemens (Dade, BN, Dimension) | >>> | 7 Negative    | 11 %  |
|                          |                                     |     | 3 Positive    | 4,9 % |
|                          | (179) Siemens                       | >>> | 3 Negative    | 4,9 % |
|                          |                                     |     | 2 Positive    | 3,3 % |
|                          | (192) Pentapharm                    | >>> | 27 Negative   | 44 %  |
|                          | (193) HYPHEN BioMed                 | >>> | 1 Negative    | 1,6 % |
| Total per sample: n = 61 |                                     |     | Success: 92 % |       |

Total success: 92 %

st\_kl

End of report

Printed: 01.12.2021